[抗体药物偶联物在肺癌治疗中的当前进展与未来发展]
[Current Progress and Future Developments of Antibody Drug Conjugates in Lung Cancer].
作者信息
Zhu Yixiang, Wang Zhijie
机构信息
CAMS Key Laboratory of Translational Research on Lung Cancer, State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing 100021, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):468-476. doi: 10.3779/j.issn.1009-3419.2022.102.22.
Abstract
Antibody drug conjugates (ADCs) are a novel class of anti-cancer drugs, which combined the specificity of monoclonal antibodies with the cytotoxic palyload via the linkers. Many ADCs have not only verified impressive activity in a variety of cancers, including breast cancer and hematological system tumors, but also in lung cancer. The aim of this study was to provide informations for practice by summarizing the mechanism of action, clinical application and problems and challenges of ADCs. .
摘要
抗体药物偶联物（ADCs）是一类新型抗癌药物，它通过连接子将单克隆抗体的特异性与细胞毒性载荷结合在一起。许多抗体药物偶联物不仅在包括乳腺癌和血液系统肿瘤在内的多种癌症中展现出了令人瞩目的活性，在肺癌中亦是如此。本研究的目的是通过总结抗体药物偶联物的作用机制、临床应用以及问题与挑战，为实际应用提供信息。
相似文献
1
[Current Progress and Future Developments of Antibody Drug Conjugates
in Lung Cancer].[抗体药物偶联物在肺癌治疗中的当前进展与未来发展]
Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):468-476. doi: 10.3779/j.issn.1009-3419.2022.102.22.
2
[Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer].[抗体药物偶联物在晚期非小细胞肺癌中的研究进展]
Zhongguo Fei Ai Za Zhi. 2022 Mar 20;25(3):214-218. doi: 10.3779/j.issn.1009-3419.2022.102.01.
3
Antibody-Drug Conjugates for Cancer Therapy.抗体药物偶联物在癌症治疗中的应用
Molecules. 2020 Oct 16;25(20):4764. doi: 10.3390/molecules25204764.
4
Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors.单克隆抗体、小分子抑制剂和抗体药物偶联物作为 HER2 抑制剂。
Curr Med Chem. 2021;28(17):3339-3360. doi: 10.2174/0929867327666200908112847.
5
Antibody-drug conjugates in solid tumors; new strategy for cancer therapy.抗体药物偶联物在实体瘤中的应用；癌症治疗的新策略。
Jpn J Clin Oncol. 2024 Aug 14;54(8):837-846. doi: 10.1093/jjco/hyae054.
6
Antibody-drug conjugates in HER2-positive breast cancer.抗体偶联药物在 HER2 阳性乳腺癌中的应用。
Chin Med J (Engl). 2021 Dec 22;135(3):261-267. doi: 10.1097/CM9.0000000000001932.
7
Antibody-drug conjugates: Principles and opportunities.抗体药物偶联物：原理与机遇。
Life Sci. 2024 Jun 15;347:122676. doi: 10.1016/j.lfs.2024.122676. Epub 2024 Apr 28.
8
Linkers Having a Crucial Role in Antibody-Drug Conjugates.连接子在抗体药物偶联物中起着关键作用。
Int J Mol Sci. 2016 Apr 14;17(4):561. doi: 10.3390/ijms17040561.
9
Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.抗体药物偶联物（ADCs）在癌症治疗中的应用：策略、挑战与成功。
J Cell Physiol. 2019 May;234(5):5628-5642. doi: 10.1002/jcp.27419. Epub 2018 Nov 27.
10
Update of antibody-drug conjugates for hematological malignancies.抗体偶联药物在血液系统恶性肿瘤中的研究进展。
Curr Opin Oncol. 2024 Sep 1;36(5):430-436. doi: 10.1097/CCO.0000000000001065. Epub 2024 Jun 28.
本文引用的文献
1
Cancer incidence and mortality in China, 2016.2016年中国癌症的发病率和死亡率
J Natl Cancer Cent. 2022 Feb 27;2(1):1-9. doi: 10.1016/j.jncc.2022.02.002. eCollection 2022 Mar.
2
Trastuzumab Deruxtecan in -Mutant Non-Small-Cell Lung Cancer.曲妥珠单抗 deruxtecan 治疗 - 突变型非小细胞肺癌。
N Engl J Med. 2022 Jan 20;386(3):241-251. doi: 10.1056/NEJMoa2112431. Epub 2021 Sep 18.
3
Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors.最近在针对实体瘤的滋养层细胞表面抗原 2 靶向治疗方面的进展。
Drug Dev Res. 2021 Dec;82(8):1096-1110. doi: 10.1002/ddr.21870. Epub 2021 Aug 30.
4
Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.抗体偶联药物在肺癌中的应用：当前治疗现状与未来发展。
Clin Lung Cancer. 2021 Nov;22(6):483-499. doi: 10.1016/j.cllc.2021.07.011. Epub 2021 Jul 25.
5
A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC.一项评估罗瓦匹妥单抗 tesirine 用于广泛期小细胞肺癌一线治疗的 1 期研究。
J Thorac Oncol. 2021 Sep;16(9):1582-1588. doi: 10.1016/j.jtho.2021.06.022. Epub 2021 Jul 6.
6
First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.人用 PF-06647020（Cofetuzumab Pelidotin）的首次研究，这是一种针对蛋白酪氨酸激酶 7 的抗体药物偶联物，用于治疗晚期实体瘤。
Clin Cancer Res. 2021 Aug 15;27(16):4511-4520. doi: 10.1158/1078-0432.CCR-20-3757. Epub 2021 Jun 3.
7
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study.罗瓦匹妥单抗替西利新作为广泛期小细胞肺癌患者一线含铂化疗后的维持治疗：来自 3 期 MERU 研究的结果。
J Thorac Oncol. 2021 Sep;16(9):1570-1581. doi: 10.1016/j.jtho.2021.03.012. Epub 2021 Apr 3.
8
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.沙库巴曲单抗戈维替康，一种 Trop-2 导向的抗体药物偶联物，用于上皮癌患者：来自 IMMU-132-01 篮子试验的 I 期/II 期的最终安全性和疗效结果。
Ann Oncol. 2021 Jun;32(6):746-756. doi: 10.1016/j.annonc.2021.03.005. Epub 2021 Mar 16.
9
Dolaflexin: A Novel Antibody-Drug Conjugate Platform Featuring High Drug Loading and a Controlled Bystander Effect.多拉氟辛：一种具有高药物负载量和可控旁观者效应的新型抗体药物偶联物平台。
Mol Cancer Ther. 2021 May;20(5):885-895. doi: 10.1158/1535-7163.MCT-20-0166. Epub 2021 Mar 15.
10
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC.一项在先前经治广泛期小细胞肺癌患者中联合纳武利尤单抗加或不加伊匹单抗应用罗瓦鲁匹妥珠单抗替西利的 1-2 期研究。
J Thorac Oncol. 2021 Sep;16(9):1559-1569. doi: 10.1016/j.jtho.2021.02.022. Epub 2021 Feb 27.
Zotero 插件